BioCryst Pharmaceuticals Inc Cash Flow-to-Debt Ratio
BioCryst Pharmaceuticals Inc cash flow-to-debt ratio. BioCryst Pharmaceuticals Inc (BCRX) has a Cash Flow-to-Debt Ratio of -0.06x as of March 2026, meaning its operating cash flow of $-62.14 Million could theoretically repay 0% of its total liabilities ($1.02 Billion) in one year. Check how aggressively does BioCryst Pharmaceuticals Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of BioCryst Pharmaceuticals Inc (1994–2025)
Cash flow-to-debt ratio of BioCryst Pharmaceuticals Inc from 1994 to 2025. Historical debt coverage capacity for BioCryst Pharmaceuticals Inc across 32 annual periods. Check BCRX cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
BioCryst Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (1994–2025)
BioCryst Pharmaceuticals Inc cash flow-to-debt ratio by year from 1994 to 2025. Year-by-year debt coverage analysis for BioCryst Pharmaceuticals Inc. For the full cash flow conversion analysis, see BioCryst Pharmaceuticals Inc (BCRX) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.52x | $329.88 Million | $633.31 Million | ▲ +1067.6% |
| 2024 | -0.05x | $-52.02 Million | $966.35 Million | ▲ +45.0% |
| 2023 | -0.10x | $-95.14 Million | $972.49 Million | ▲ +48.9% |
| 2022 | -0.19x | $-161.85 Million | $844.60 Million | ▲ +6.3% |
| 2021 | -0.20x | $-142.16 Million | $695.14 Million | ▲ +47.2% |
| 2020 | -0.39x | $-137.22 Million | $353.98 Million | ▲ +40.7% |
| 2019 | -0.65x | $-89.58 Million | $137.03 Million | ▲ +31.1% |
| 2018 | -0.95x | $-92.56 Million | $97.61 Million | ▼ -117.8% |
| 2017 | -0.44x | $-41.14 Million | $94.49 Million | ▲ +28.1% |
| 2016 | -0.61x | $-53.44 Million | $88.27 Million | ▼ -254.6% |
| 2015 | -0.17x | $-13.12 Million | $76.83 Million | ▲ +72.9% |
| 2014 | -0.63x | $-38.55 Million | $61.24 Million | ▼ -18.6% |
| 2013 | -0.53x | $-26.53 Million | $49.99 Million | ▲ +17.8% |
| 2012 | -0.65x | $-37.40 Million | $57.89 Million | ▼ -35.0% |
| 2011 | -0.48x | $-32.25 Million | $67.40 Million | ▲ +26.4% |
| 2010 | -0.65x | $-28.55 Million | $43.94 Million | ▼ -124.1% |
| 2009 | -0.29x | $-16.22 Million | $55.92 Million | ▲ +46.8% |
| 2008 | -0.55x | $-20.87 Million | $38.27 Million | ▼ -69.8% |
| 2007 | -0.32x | $-25.00 Million | $77.81 Million | ▲ +0.0% |
| 2006 | -0.32x | $-15.21 Million | $47.33 Million | ▲ +43.8% |
| 2005 | -0.57x | $-23.35 Million | $40.81 Million | ▲ +90.1% |
| 2004 | -5.79x | $-18.15 Million | $3.13 Million | ▲ +14.7% |
| 2003 | -6.79x | $-11.20 Million | $1.65 Million | ▲ +51.3% |
| 2002 | -13.96x | $-16.36 Million | $1.17 Million | ▼ -213.6% |
| 2001 | -4.45x | $-10.16 Million | $2.28 Million | ▼ -1208.9% |
| 2000 | -0.34x | $-3.18 Million | $9.35 Million | ▲ +86.1% |
| 1999 | -2.45x | $-4.90 Million | $2.00 Million | ▲ +18.3% |
| 1998 | -3.00x | $-4.20 Million | $1.40 Million | ▲ +65.0% |
| 1997 | -8.58x | $-10.30 Million | $1.20 Million | ▼ -114.6% |
| 1996 | -4.00x | $-6.80 Million | $1.70 Million | ▲ +6.5% |
| 1995 | -4.28x | $-7.70 Million | $1.80 Million | ▼ -5.3% |
| 1994 | -4.06x | $-6.50 Million | $1.60 Million | — |